Valuation: Exagen Inc.

Market Cap 212M 186M 175M 160M 298M 20.28B 301M 2.1B 813M 10.34B 795M 778M 33.53B P/E 2026 *
-13.3x
P/E 2027 * -17x
Enterprise Value 212M 186M 175M 160M 298M 20.28B 301M 2.1B 813M 10.34B 795M 778M 33.53B EV / Sales 2026 *
2.86x
EV / Sales 2027 * 2.6x
Free-Float
58.04%
Yield 2026 *
-
Yield 2027 * -
1 day-3.43%
1 week+8.77%
Current month+15.29%
1 month+10.61%
3 months+94.31%
6 months+196.91%
Current year+39.18%
1 week 7.65
Extreme 7.65
8.88
1 month 6.83
Extreme 6.83
8.88
Current year 2.59
Extreme 2.59
8.88
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.85
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 2022-10-16
Director of Finance/CFO 57 2024-08-31
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Chairman 72 2023-01-18
Director/Board Member 63 2019-07-29
Director/Board Member 56 2021-06-16
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Sell

Chief Financial Officer

-22,185 0.0916%
3/12/26 Free

Chief Financial Officer

126,511 0.5582%
3/12/26 Free

Chief Executive Officer

250,000 1.1031%
Change 5-day change 1-year change 3-year change Capi.($)
-3.49%+8.77%-14.70%+277.77% 212M
+0.86%+13.62%+127.02%+768.06% 56.35B
-2.12%-5.92%+9.06%+46.49% 25.27B
-0.63%-1.76%-14.56%-37.88% 6.72B
+0.20%-2.07%-3.92%+162.88% 5.82B
+0.76%+0.94%+13.58%+64.50% 3.34B
-3.16%-9.89%-27.73%+2,359.10% 2.71B
-1.80%-1.69%+129.03%+50.65% 2.43B
+17.83%+3.09%+36.88%+45.18% 2.35B
+0.03%+8.07%-4.00%-53.40% 1.98B
Average +0.85%+2.61%+25.07%+368.34% 10.72B
Weighted average by Cap. +0.20%+4.96%+71.15%+484.60%

Financials

2026 *2027 *
Net sales 73.91M 64.87M 60.98M 55.75M 104M 7.08B 105M 732M 284M 3.61B 278M 271M 11.7B 81.51M 71.55M 67.25M 61.49M 115M 7.81B 116M 808M 313M 3.98B 306M 299M 12.91B
Net income -15.93M -13.98M -13.15M -12.02M -22.46M -1.53B -22.63M -158M -61.21M -778M -59.83M -58.52M -2.52B -13.38M -11.74M -11.04M -10.09M -18.86M -1.28B -19M -133M -51.4M -653M -50.25M -49.14M -2.12B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26-09-23 US$8.445 -3.38% 180,748
26-09-22 US$8.740 +1.39% 265,124
26-09-21 US$8.620 +2.50% 361,655
26-09-18 US$8.410 +6.86% 351,726
26-09-17 US$7.870 +1.16% 195,435
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.740USD
Average target price
10.14USD
Spread / Average Target
+16.05%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!